

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/074270 A2

(51) International Patent Classification⁷: **C07D 309/32**,
405/06, 409/10, 413/10, 407/10, 413/12, 407/06, 405/12,
407/12, 417/10, 409/06, 471/04, 487/04, 285/06, 405/10,
413/06, 417/06, 495/04, 513/04, 405/14, 413/14, 417/12,
473/36, 473/30, A61K 31/351, A61P 31/14

John, Howard [US/US]; Agouron Pharmaceuticals, Inc.,
A Pfizer Company, 10777 Science Center Drive, San
Diego, CA 92121 (US).

(21) International Application Number:
PCT/IB2004/000493

(74) Agent: **LUMB, J., Trevor**; Pfizer Inc. c/o Jackie
Lawrence, Eastern Point Road, Mailstop 8260-1615,
Groton, CT 06340 (US).

(22) International Filing Date: 9 February 2004 (09.02.2004)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/449,088 21 February 2003 (21.02.2003) US
60/472,355 20 May 2003 (20.05.2003) US

(71) Applicant (for all designated States except US): **PFIZER
INC.** [US/US]; 235 East 42nd Street, New York, NY 10017
(US).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **BORCHARDT,
Allen, John** [US/US]; 5419 Via Carancho, San Diego,
CA 92111 (US). **GONZALEZ, Javier** [US/US]; Agouron
Pharmaceuticals, Inc., A Pfizer Company, 10777 Sci-
ence Center Drive, San Diego, CA 92121 (US). **LI, Hui**
[CN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Com-
pany, 10777 Science Center Drive, San Diego, CA 92121
(US). **LINTON, Maria, Angelica** [US/US]; Agouron
Pharmaceuticals, Inc., A Pfizer Company, 10777 Science
Center Drive, San Diego, CA 92121 (US). **TATLOCK,**

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME



(57) Abstract: The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R¹ and R², are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).



WO 2004/074270 A2